Prostate Cancer - Results from #180

Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. April 8, 2022

Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. April 8, 2022

Safety of stereotactic body radiation therapy for localized prostate cancer without treatment planning MRI. April 8, 2022

Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance. April 7, 2022

Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis. April 7, 2022

ADXS31-142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer:  Open-Label Phase I/II KEYNOTE-046 Study. April 7, 2022

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd? April 7, 2022

Impact of Music on Postoperative Pain, Anxiety, and Narcotic Use After Robotic Prostatectomy: A Randomized Controlled Trial. April 7, 2022

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. April 7, 2022

[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. April 6, 2022

Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients. April 6, 2022

Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study). April 6, 2022

Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations. April 6, 2022

Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK. April 6, 2022

Foundation Medicine and Collaborators to Share Scientific Advances at AACR22 Reinforcing the Power of Genomic Testing in Precision Cancer Care April 5, 2022

Phase 1b/2 Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. April 5, 2022

Value of the capsular enhancement sign on dynamic contrast-enhanced prostate multiparametric MRI for the detection of extracapsular extension. April 5, 2022

Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. April 5, 2022

Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. April 5, 2022

Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. April 5, 2022

Page 10 of 1224

email news signup